These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 34053732)

  • 1. France's competitiveness in global pharmaceutical research: The situation is improving.
    d'Andon A; Galaup A; Fabron C; Detournay B; Borel T
    Therapie; 2021; 76(6):549-557. PubMed ID: 34053732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Attractiveness of France for international clinical research: 8th survey conducted by Leem (French association for pharmaceutical companies)].
    Galaup A; Barthélémy P; Pouletty-Lefebvre B; Béhier JM; Zetlaoui J; Borel T
    Therapie; 2018 Oct; 73(5):367-376. PubMed ID: 29753391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Attractiveness of France for international clinical trials in 2012: 6(th) survey assessed by Leem (French association of pharmaceutical companies)].
    Lassale C; Sibenaler C; Béhier JM; Barthélémy P; Plétan Y; Courcier S
    Therapie; 2013; 68(1):1-18. PubMed ID: 23484655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [France, an attractive country for international clinical research: 2008 survey assessed by Leem (French association of pharmaceutical companies)].
    Lassale C; Sibenaler C; Béhier JM; Plétan Y; Courcier S;
    Therapie; 2008; 63(5):345-57. PubMed ID: 19154705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [France, an attractive country for international clinical research: 2010 survey assessed by Leem (French association of pharmaceutical companies)].
    Lassale C; Sibenaler C; Behier JM; Pletan Y; Courcier S
    Therapie; 2011; 66(1):1-15. PubMed ID: 21466772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The attractive position of France in international clinical research: 2006 survey assessed by Leem (French pharmaceutical companies)].
    Courcier S; Sibenaler C; Couderc M; Trinquet F; Plétan Y; Lassale C;
    Therapie; 2006; 61(5):407-18. PubMed ID: 17243270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The pharmaceutical industry in France: the turning point of 1915].
    Bonnemain B
    Rev Hist Pharm (Paris); 2015 Dec; 63(388):399-422. PubMed ID: 26827550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Attractiveness of France for clinical trials: evaluation of laboratories and promoters].
    d'Enfert J; Lassale C; Prod'homme P
    Therapie; 2003; 58(3):283-9. PubMed ID: 14655322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A survey on the position of France in international clinical research as assessed by pharmaceutical laboratories].
    Courcier-Duplantier S; Bouhours P; Pinton P; Sibenaler C; Lassale C;
    Therapie; 2004; 59(6):629-38. PubMed ID: 15789827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Impact of COVID-19 on the Conduct of Clinical Trials for Medical Products in Korea.
    Jeon J; Kim H; Yu KS
    J Korean Med Sci; 2020 Sep; 35(36):e329. PubMed ID: 32924344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Not Available].
    Lassale C; Sibenaler C; Béhier JM; Plétan Y; Courcier S
    Therapie; 2008; 63(5):345-57. PubMed ID: 27392656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Not Available].
    Courcier S; Sibenaler C; Couderc M; Trinquet F; Plétan Y; Lassale C; le Groupe de Travail Attractivité de la France du Leem
    Therapie; 2006; 61(5):407-18. PubMed ID: 27392823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The new regulatory tools of the 2016 Health Law to fight drug shortages in France.
    Bocquet F; Degrassat-Théas A; Peigné J; Paubel P
    Health Policy; 2017 May; 121(5):471-476. PubMed ID: 28366432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trends of Phase I Clinical Trials in the Latest Ten Years across Five European Countries.
    Di Tonno D; Perlin C; Loiacono AC; Giordano L; Martena L; Lagravinese S; Rossi F; Marsigliante S; Maffia M; Falco A; Piscitelli P; Miani A; Esposito S; Distante A; Argentiero A
    Int J Environ Res Public Health; 2022 Oct; 19(21):. PubMed ID: 36360902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The conduct of clinical trials for medicinal products in europe in the light of the European clinical trials directive. Review of regulatory and practical aspects in the different countries.
    Dubray C; Maillere P; Spriet A;
    Therapie; 2007; 62(3):193-7, 199-202. PubMed ID: 17803885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Difficulties with conducting clinical trials in France].
    Zannad F; Plétan Y
    Therapie; 2001; 56(4):341-7. PubMed ID: 11677850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Key cost drivers of pharmaceutical clinical trials in the United States.
    Sertkaya A; Wong HH; Jessup A; Beleche T
    Clin Trials; 2016 Apr; 13(2):117-26. PubMed ID: 26908540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Public-private partnership models in France and in Europe.
    Demotes-Mainard J; Canet E; Segard L
    Therapie; 2006; 61(4):325-34, 313-23. PubMed ID: 17124948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the Speed of Enrollment for Clinical Trials Conducted by Japanese and Global Pharmaceutical Companies.
    Maeda H; Yamanoi M; Fukuda Y; Inaba Y
    Biol Pharm Bull; 2023; 46(9):1289-1295. PubMed ID: 37661408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J; Puech A; Boissel JP;
    Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.